What Is IGF-1 DES(1-3)? The Truncated IGF-1 Variant, Compared to LR3
DES(1-3)IGF-1 is a natural truncated IGF-1 missing three N-terminal residues, giving reduced IGFBP binding, higher in-vitro potency and a short half-life.
DES(1-3)IGF-1 is a naturally occurring form of IGF-1 lacking its first three N-terminal residues (Gly-Pro-Glu). Removing Glu-3 sharply lowers binding to IGF-binding proteins, which in cell and animal studies raised its potency roughly tenfold but left it short-acting.
DES(1-3)IGF-1 is one of the more instructive molecules in the insulin-like growth factor literature, because it isolates a single idea: what happens to a growth factor when you strip away the short N-terminal handle that its binding proteins grab onto. Take the first three residues off IGF-1 and, in the assays where this was studied, the molecule became several times more active while simultaneously becoming far shorter-lived in circulation. That paired tradeoff — more free potency, less persistence — is the whole story, and it is the mirror image of how the long-acting analogue LR3 is built. Everything below describes laboratory and animal findings, not use in people or any other organism.
What is DES(1-3)IGF-1, structurally?
Full-length human IGF-1 is a 70-amino-acid single-chain polypeptide. DES(1-3)IGF-1 — written as des-(1-3)-IGF-1 or destripeptide IGF-1 — is that same molecule with its first three N-terminal residues removed: Gly-Pro-Glu at positions 1, 2 and 3. What remains is a 67-residue peptide that is otherwise identical to intact IGF-1, including the folded core and receptor-binding surface.1 For identity cross-reference, the variant carries CAS 112603-35-7 and UNII AG0WVP88OA.13
It is worth being clear that this is not purely a synthetic construct. DES(1-3)IGF-1 is a real endogenous species. It was purified and sequenced from bovine colostrum, and the same truncated form has been identified in human fetal and adult brain and in porcine uterus, arising through post-translational proteolytic cleavage of IGF-1.145 The colostrum work in particular sequenced the natural truncated peptide directly and confirmed the missing tripeptide, alongside intact IGF-1 and IGF-2.4
Why does removing three residues change so much?
The interesting part is that a tiny deletion at one end of the chain produces an outsized functional shift, and the literature traces that shift to a specific residue. Structure-function work on the N-terminus pinpointed the region — and Glu-3 in particular — as the determinant of binding to the IGF-binding proteins.6 A bovine IGFBP purified from conditioned medium was shown to require the N-terminal tripeptide of IGF-1 for binding at all; strip the tripeptide and affinity for that binding protein collapses.2
That matters because in normal physiology the great majority of IGF-1 is not free. It circulates bound to IGFBPs, which act as reservoirs and buffers, holding the growth factor away from its receptor. A variant that binds those proteins poorly stays disproportionately free, and free IGF is the fraction that can engage the type-1 IGF receptor. So the potency gain is a sequestration effect, not a receptor effect.
~100x lower affinity for a low-molecular-weight IGF-binding protein was reported for the brain-derived truncated form versus intact IGF-1.
The receptor data make this explicit. In L6 myoblasts, destripeptide IGF-1 stimulated protein synthesis roughly sevenfold more than intact IGF-1, yet it showed no increased ability to compete for IGF-1 receptor binding — the extra activity had to come from somewhere other than the receptor.3 Recombinant and brain-derived truncated IGF-1 showed about a hundredfold reduced affinity for a low-MW IGF-binding protein and four times greater stimulation of DNA synthesis in fetal rat brain cells; crucially, its activity was unaffected by a binding protein that abolished the activity of intact IGF-1.5
The potency of DES(1-3)IGF-1 is a story about what it stops binding, not what it binds harder.
Systematic affinity measurements across IGFBP-1 through -4 for IGF-1 and its analogues provide the comparative dataset behind these claims, quantifying how much the reduced-binding variants shed IGFBP interaction relative to the intact hormone.12 Pulling the numbers together: the commonly cited figure is that DES(1-3)IGF-1 is around tenfold more potent than IGF-1 in cultured cells, though the honest range across assays and cell lines runs roughly four- to tenfold.145
The other half of the tradeoff: it is short-acting
Reduced IGFBP binding cuts both ways. Those same binding proteins are what keep IGF-1 in circulation; bound hormone is protected from clearance. A variant that stays free is also a variant that gets cleared quickly. In rats, radiolabelled DES(1-3)IGF-1 remained largely unbound in plasma and was cleared much faster than intact IGF-1 — clearance of 4.59 versus 1.20 ml/min/kg — with a larger volume of distribution and greater uptake into gut and other tissues.7
So the molecule buys higher local, free potency at the cost of persistence. That is the defining property to hold in mind when comparing it to engineered long-acting analogues.
DES(1-3) versus IGF-1 LR3
IGF-1 LR3 — Long-[Arg3]-IGF-I — is the analogue most often discussed alongside DES(1-3), and the comparison is genuinely illuminating because the two arrive at « binds IGFBPs poorly » from opposite directions. DES(1-3) gets there by deletion: remove the tripeptide, lose the IGFBP handle, stay short-acting. LR3 gets there by addition and substitution: it keeps the full chain but adds a 13-residue N-terminal extension and swaps in Arg at position 3, which both weakens IGFBP binding and — importantly — makes the molecule long-acting.10
The fusion-protein analogue work that defined the LR3 class is also the cleanest demonstration that the potency gain is IGFBP-mediated rather than intrinsic. In IGFBP-secreting cells the potency order was Long[Arg3] and des(1-3) at the top, then Long[Gly3], then Long-IGF-I, then IGF-1. But in IGFBP-free fibroblasts the ranking inverted: LR3 was actually less potent than IGF-1.10 Take the binding proteins out of the system and the « super-potency » evaporates, which tells you it was never about the receptor.
| Property | DES(1-3)IGF-1 | IGF-1 LR3 |
|---|---|---|
| Chain change vs IGF-1 | Deletes N-terminal Gly-Pro-Glu (67 aa) | Adds 13-aa N-terminal extension + Arg-3 substitution |
| IGFBP binding | Sharply reduced (loss of Glu-3) | Sharply reduced (Arg-3 + extension) |
| Source of potency | Reduced IGFBP sequestration | Reduced IGFBP sequestration |
| Duration (animal PK) | Short-acting; rapidly cleared | Long-acting by design |
| Origine | Natural endogenous variant | Engineered recombinant analogue |
Comparison drawn from in-vitro and animal literature only. No entry describes human use; all potency and pharmacokinetic values are assay- or species-specific.
Direct head-to-head studies of the two variants do exist, which is what makes this comparison factual rather than inferred. In catabolic (dexamethasone-treated) rats, both DES(1-3)IGF-I and LR3IGF-I were severalfold more potent than IGF-1 at inducing gut growth, with in-vivo potency tracking reduced IGFBP interaction.8 In diabetic rats, the two IGFBP-poor-binding variants were about 2.5- to 3-fold more potent than IGF-1 at restoring growth.9 And an explicit three-way pharmacokinetic study compared clearance of IGF-1, DES(1-3)IGF-I and LR3IGF-I side by side, both analogues selected precisely because they bind IGFBPs poorly.11 For the broader family, see our overviews of IGF-1 LR3 and of IGF-1, mTOR and muscle signalling, as well as the related growth hormone secretagogues.
An honest read of the evidence
The DES(1-3) story is unusually coherent, but that coherence comes with caveats worth stating plainly. First, the evidence base is old and concentrated. Most of the foundational potency, mechanism and clearance work dates from roughly 1987 to 1996 and came from a single research lineage — the CSIRO and Adelaide group (Ballard, Francis, Wallace, Tomas, Read and colleagues) authored the bulk of it.137 That is a lot of internally consistent data from one place, and independent replication is comparatively thin. Consistency within a lineage is not the same as independent confirmation.
Second, everything is in vitro or in animals. The findings come from L6 myoblasts, fetal brain cells and hepatoma lines, and from rats, pigs and marmosets. There are no human clinical efficacy or safety data for DES(1-3)IGF-1 at all. Third, the headline « about tenfold more potent » figure is genuinely assay- and cell-line-dependent, spanning roughly four- to tenfold and sometimes lower; it should be read as an approximate, context-bound number rather than a fixed constant.15 Fourth, the short-half-life and rapid-clearance data are largely rodent pharmacokinetics; species extrapolation is uncertain and human PK is simply unknown.711
Finally, IGF-1 signalling is mitogenic by nature. As with any IGF-1 variant, growth-promoting activity carries a theoretical proliferative concern that has not been characterised for DES(1-3) in humans — which is one more reason the strict research-use framing here is not boilerplate. Condor Research does not list DES(1-3)IGF-1 as a confirmed catalogue product, and this article makes no product-specific purity, COA or availability claim.
All materials referenced here are discussed strictly as Research Use Only (RUO). Every statement above describes in-vitro assays or animal studies drawn from the published literature. Nothing here is a dosing protocol, clinical guidance, or a safety assessment for humans, animals, or any other organism, and none of it implies or endorses administration to living subjects.
Condor Research · Service scientifique
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com
- DES(1-3)IGF-1 is a 67-amino-acid truncated form of the 70-residue IGF-1, missing the N-terminal tripeptide Gly-Pro-Glu.
- It is a genuine endogenous variant, isolated from bovine colostrum, human brain and porcine uterus, formed by proteolytic cleavage of IGF-1.
- Deleting the single residue Glu-3 is what lowers affinity for the IGF-binding proteins (IGFBPs), and that reduced binding — not stronger receptor binding — drives its higher potency.
- Reported in-vitro potency versus intact IGF-1 is commonly around tenfold, with published values ranging roughly four- to tenfold depending on assay and cell line.
- Because it stays largely free in plasma rather than bound to IGFBPs, it is cleared much faster than IGF-1 (rat clearance 4.59 vs 1.20 ml/min/kg), so it is short-acting.
- IGF-1 LR3 uses the opposite design logic: it also binds IGFBPs poorly but adds an N-terminal extension and an Arg-3 substitution that make it long-acting.
- All evidence is in vitro and in animals; there is no approved human therapeutic use and no EMA or FDA authorisation for DES(1-3)IGF-1.
What does "DES(1-3)" actually mean?
It denotes deletion ("des") of residues 1 through 3 from IGF-1 — the N-terminal tripeptide Gly-Pro-Glu. The result is a 67-amino-acid peptide rather than the 70-residue full-length hormone.
Is DES(1-3)IGF-1 a natural molecule?
Yes. It is an endogenous variant formed by proteolytic cleavage of IGF-1 and has been purified from bovine colostrum, human brain and porcine uterus. It can also be produced recombinantly for research.
Why is it more potent than ordinary IGF-1 in the lab?
Because it binds the IGF-binding proteins poorly, chiefly through loss of Glu-3, so more of it remains free to reach the receptor. In L6 myoblasts it was about sevenfold more active than IGF-1 without any increase in receptor competition, which localises the effect to reduced IGFBP sequestration.
How is it different from IGF-1 LR3?
Both bind IGFBPs weakly, but DES(1-3) does so by deleting three residues and stays short-acting, whereas LR3 adds an N-terminal extension and an Arg-3 substitution that make it long-acting. Studies comparing the two directly exist in gut-growth, diabetic-rat and clearance models.
How reliable is the "tenfold more potent" claim?
It is a useful rule of thumb but not a constant. Reported multiples range from roughly four- to tenfold depending on the assay and cell line, and in IGFBP-free systems the advantage can disappear entirely. Treat it as approximate.
Is DES(1-3)IGF-1 approved for any human or veterinary use?
No. There is no EMA or FDA authorisation and no approved human therapeutic use anywhere. The entire evidence base is cell-culture and animal research, and it is handled strictly as Research Use Only.